RESEARCH TRIANGLE PARK, N.C., Feb. 23 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that founder and CEO George Painter, Ph.D., will join representatives from government, industry and academia in an Institute of Medicine Workshop focusing on improving innovation around the discovery and development of new products needed to undertake medical countermeasures (e.g. vaccines, drugs, and diagnostics) when responding to public health emergencies. The workshop, "The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval," is being held at The National Academy of Sciences Building in Washington, D.C., on February 23-24, 2010.
The workshop will examine federal policies and activities relevant to the discovery and through the approval of products integral to undertaking medical countermeasures for responding to public health emergencies, such as a bioterrorist attack or a pandemic outbreak with the potential to rapidly overwhelm existing public health and medical systems. Dr. Painter will participate on a panel convened to address procuring and improving scientific innovation based on an assessment of national biodefense priorities. The panel, "Opportunities for enhancing translation of basic science: models to improve innovation that responds to national priorities," will also examine current investment in basic research and identify potential other models to optimize the medical countermeasures product pipeline.
Chimerix's lead compound, CMX001, is being developed as a biodefense countermeasure in the event of smallpox release in addition to use in antiviral applications. CMX001 is also currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections for immunocompromised patient populations.
About Chimerix
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. CMX157 is a late-stage preclinical candidate being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company's extensive chemical library, Chimerix also has an aggressive effort in translational medicine addressing malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.
SOURCE Chimerix, Inc.
Advertisement
The workshop will examine federal policies and activities relevant to the discovery and through the approval of products integral to undertaking medical countermeasures for responding to public health emergencies, such as a bioterrorist attack or a pandemic outbreak with the potential to rapidly overwhelm existing public health and medical systems. Dr. Painter will participate on a panel convened to address procuring and improving scientific innovation based on an assessment of national biodefense priorities. The panel, "Opportunities for enhancing translation of basic science: models to improve innovation that responds to national priorities," will also examine current investment in basic research and identify potential other models to optimize the medical countermeasures product pipeline.
Advertisement
Chimerix's lead compound, CMX001, is being developed as a biodefense countermeasure in the event of smallpox release in addition to use in antiviral applications. CMX001 is also currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections for immunocompromised patient populations.
About Chimerix
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. CMX157 is a late-stage preclinical candidate being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company's extensive chemical library, Chimerix also has an aggressive effort in translational medicine addressing malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.
SOURCE Chimerix, Inc.
